Thus, overexpression of SphK1 in chronic myelogenous leukemia (CML) can increase resistance to the tyrosine kinase inhibitor imatinib by enhancing the stability of its target, the mutated kinase BCR-ABL. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.